Daniels Eric Joseph 4

What Happened Eric Joseph Daniels, Chief Development Officer of PLUS Therapeutics (PSTV), was granted two derivative awards on April 20, 2026 — 20,000 and 20,000 units (40,000 total). Each grant shows a $0 acquisition price (these are awards/derivative grants, not open-market purchases). The filing’s footnotes indicate one award is a Restricted Stock Unit (RSU) with a time-based vesting schedule and the other includes option-style vesting terms.

Key Details

• Transaction date: 2026-04-20; Form 4 filed 2026-04-22 (appears filed timely).
• Grants: two awards of 20,000 each = 40,000 total derivative units; reported price $0.
• Footnote F1: Each RSU equals a contingent right to one common share; one‑third vest on July 1, 2027, remainder vests ratably over the next eight quarters (substantially equal increments).
• Footnote F2: Vesting schedule for option-style award — 1/4 vests on April 20, 2027, then 1/36th of the remaining options vest monthly thereafter.
• Shares owned after the transaction: not disclosed in the provided excerpt.

Context These awards are compensation-related grants subject to vesting and are not immediate purchases or sales. RSUs and similar option awards typically do not represent immediately tradable shares until they vest (and any tax-withholding is satisfied). Such grants are common for executive compensation; they indicate future upside exposure tied to the company’s stock but do not, by themselves, signal an insider buying or selling intent.